Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

54.5%

6 terminated/withdrawn out of 11 trials

Success Rate

14.3%

-72.2% vs industry average

Late-Stage Pipeline

9%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
5(55.6%)
Phase 2
3(33.3%)
Phase 3
1(11.1%)
9Total
Phase 1(5)
Phase 2(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials
NCT05354141Phase 3Recruiting

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

Role: lead

NCT06918808Phase 2Recruiting

DB-3Q bmMSC-EVs in Patients With Perianal Fistulizing Crohn's Disease

Role: lead

NCT05130983Phase 1Terminated

Study of ExoFlo for the Treatment of Medically Refractory Crohn's Disease

Role: lead

NCT05836883Phase 1Terminated

Study of ExoFlo for the Treatment of Perianal Fistulas

Role: lead

NCT05176366Phase 1Terminated

Study of ExoFlo for the Treatment of Medically Refractory Ulcerative Colitis

Role: lead

NCT04657458Unknown

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

Role: lead

NCT05116761Phase 1Withdrawn

ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome

Role: lead

NCT05215288Unknown

Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients

Role: lead

NCT05127122Phase 1Withdrawn

Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for ARDS

Role: lead

NCT05125562Phase 2Withdrawn

Extracellular Vesicles Infusion Treatment for Mild-to-Moderate COVID-19

Role: lead

NCT04493242Phase 2Completed

Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS

Role: lead

All 11 trials loaded